Using machine learning to predict side effects of radiotherapy in cancer patients
Hamlet-RT: Heuristics, Algorithms and Machine Learning: Evaluation & Testing in Radiation Therapy
This study is trying to see if using advanced computer techniques can help predict which cancer patients might experience serious side effects from their radiotherapy treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 310 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cambridge University Hospitals NHS Foundation Trust Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Cambridge, Cambridgeshire) |
| Trial ID | NCT04060706 on ClinicalTrials.gov |
What this trial studies
The Hamlet.rt study collects data and patient questionnaires from individuals undergoing image-guided radiotherapy with the goal of predicting the risk of significant side effects from treatment. By utilizing novel machine learning and mathematical techniques, the study aims to create a predictive model based on normal tissue dose calculations and patient characteristics. This model will be continuously updated throughout the patient's treatment journey. Additionally, the study seeks to establish a shared data resource to facilitate further research in machine learning and medical image processing for radiation therapy.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with primary prostate cancer, head and neck cancer, lung cancer, or brain tumors who are suitable for radical image-guided radiotherapy.
Not a fit: Patients who are not willing or able to complete the required study protocols, including web-based questionnaires, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment plans that minimize side effects for cancer patients undergoing radiotherapy.
How similar studies have performed: Other studies utilizing machine learning in radiation therapy have shown promise, indicating that this approach may lead to significant advancements in patient care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Male or Female * Aged 18 years or older * Diagnosed with primary prostate cancer, head and neck cancer, lung cancer, or brain tumour * Treated with curative intent * Suitable for radical image guided radiotherapy * WHO ECOG performance status 0 or 1 * Expected survival of 18 months or more Exclusion Criteria: * Participant is not willing or able to complete the protocol-stated requirements of the study, e.g. accessing \& completing web-based long-term follow-up questionnaires.
Where this trial is running
Cambridge, Cambridgeshire
- Cambridge University Hospitals NHS Foundation Trust — Cambridge, Cambridgeshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Raj Dr. Jena — Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge
- Study coordinator: Meena Murthy
- Email: meena.murthy@addenbrookes.nhs.uk
- Phone: 01223 349707
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.